JP2022523704A - 医薬組成物 - Google Patents

医薬組成物 Download PDF

Info

Publication number
JP2022523704A
JP2022523704A JP2021543509A JP2021543509A JP2022523704A JP 2022523704 A JP2022523704 A JP 2022523704A JP 2021543509 A JP2021543509 A JP 2021543509A JP 2021543509 A JP2021543509 A JP 2021543509A JP 2022523704 A JP2022523704 A JP 2022523704A
Authority
JP
Japan
Prior art keywords
fatty acid
pharmaceutical composition
acid
composition according
chain fatty
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021543509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523704A5 (https=
Inventor
ワン，ゼレン
チェン，シュン
Original Assignee
シェンチェン・ファーマシン・カンパニー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シェンチェン・ファーマシン・カンパニー・リミテッド filed Critical シェンチェン・ファーマシン・カンパニー・リミテッド
Publication of JP2022523704A publication Critical patent/JP2022523704A/ja
Publication of JP2022523704A5 publication Critical patent/JP2022523704A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021543509A 2019-01-25 2020-01-20 医薬組成物 Pending JP2022523704A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/073112 2019-01-25
CN2019073112 2019-01-25
PCT/CN2020/073099 WO2020151633A1 (en) 2019-01-25 2020-01-20 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
JP2022523704A true JP2022523704A (ja) 2022-04-26
JP2022523704A5 JP2022523704A5 (https=) 2023-01-31

Family

ID=71736646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543509A Pending JP2022523704A (ja) 2019-01-25 2020-01-20 医薬組成物

Country Status (5)

Country Link
US (1) US20220193095A9 (https=)
EP (1) EP3914234A4 (https=)
JP (1) JP2022523704A (https=)
CN (1) CN113473974A (https=)
WO (1) WO2020151633A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10792292B2 (en) 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
CN114762693A (zh) * 2020-12-31 2022-07-19 成都海博为药业有限公司 一种载药量高的阿比特龙药物组合物及其制备方法及用途
US11957696B2 (en) 2021-02-15 2024-04-16 Propella Therapeutics, Inc. Abiraterone prodrugs
JP2024512659A (ja) * 2021-04-01 2024-03-19 アール．ピー．シェーラー テクノロジーズ，エルエルシー 医薬製剤におけるアニオン性キレート剤としてのリン脂質
JP2024533332A (ja) * 2021-09-08 2024-09-12 プロペラ セラピューティクス インコーポレイテッド 経口アビラテロン製剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH024712A (ja) * 1988-06-24 1990-01-09 Eisai Co Ltd ビタミンｅ又はその誘導体の吸収促進組成物
WO2008044659A1 (en) * 2006-10-06 2008-04-17 Kaneka Corporation Highly absorbable composition for oral administration containing oxidized coenzyme q10
JP2013516433A (ja) * 2009-12-31 2013-05-13 ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ，エルエルシー ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節
JP2015515970A (ja) * 2012-05-04 2015-06-04 ヤゴテック アーゲー アビラテロン酢酸エステルを含む薬学的組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030009416A (ko) * 2000-04-04 2003-01-29 시오노기세이야쿠가부시키가이샤 고지용성 약물을 함유하는 유성 조성물
EP1959926A1 (en) * 2005-10-25 2008-08-27 Abbott Laboratories Formulation comprising a drug of low water solubility and method of use thereof
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
GB2488788B (en) * 2011-03-07 2013-07-10 Natco Pharma Ltd Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response
CN103169712B (zh) * 2011-12-20 2017-10-27 重庆华邦制药有限公司 提高生物利用度的度他雄胺制剂及其制备方法
KR20140043579A (ko) * 2012-09-24 2014-04-10 한국콜마주식회사 무복계면 디클로페낙나트륨 및 그 제조방법
US20140287039A1 (en) * 2013-03-15 2014-09-25 Iceutica Inc. Abiraterone Acetate Formulation
SG11201701139YA (en) * 2014-09-18 2017-03-30 Iceutica Inc Abiraterone acetate formulation and methods of use
WO2017037647A1 (en) * 2015-09-02 2017-03-09 Leiutis Pharmaceuticals Pvt Ltd Stable pharmaceutical compositions of abiraterone
CN105055314A (zh) * 2015-09-28 2015-11-18 杭州安德科技有限公司 一种阿比特龙的口腔喷雾剂及其使用和制备方法
CA2922959C (en) * 2016-03-03 2018-01-02 Pankaj Modi Orally administrable composition

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH024712A (ja) * 1988-06-24 1990-01-09 Eisai Co Ltd ビタミンｅ又はその誘導体の吸収促進組成物
WO2008044659A1 (en) * 2006-10-06 2008-04-17 Kaneka Corporation Highly absorbable composition for oral administration containing oxidized coenzyme q10
JP2013516433A (ja) * 2009-12-31 2013-05-13 ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ，エルエルシー ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節
JP2015515970A (ja) * 2012-05-04 2015-06-04 ヤゴテック アーゲー アビラテロン酢酸エステルを含む薬学的組成物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
INTERNATIONAL JOURNAL OF NANOMEDICINE, vol. 12, JPN6023043304, 2017, pages 4869 - 4878, ISSN: 0005324628 *
オレオサイエンス, vol. 18, no. 8, JPN6023043305, 2018, pages 29 - 35, ISSN: 0005324627 *

Also Published As

Publication number Publication date
US20220193095A9 (en) 2022-06-23
CN113473974A (zh) 2021-10-01
WO2020151633A1 (en) 2020-07-30
EP3914234A1 (en) 2021-12-01
EP3914234A4 (en) 2022-09-14
US20200237784A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
JP2022523704A (ja) 医薬組成物
JP7394974B2 (ja) 酢酸アビラテロンを含む医薬組成物、並びにその製造方法及び使用
US10286077B2 (en) Steroid hormone compositions in medium chain oils
US20170281647A1 (en) Steroid hormone compositions in medium chain oils
JP2017516768A (ja) 天然の併用ホルモン補充療法剤及び療法
WO2014009434A1 (en) Self-microemulsifying drug delivery system of abiraterone or abiraterone acetate
US11123351B2 (en) Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
JP2022518356A (ja) レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物
JP2022523704A5 (https=)
CN114344309A (zh) 一种别孕烷醇酮衍生物自乳化制剂及其制备方法
JP2009518443A (ja) 脂質を主材料とする担体に内封された、不溶性小分子治療剤の製剤
AU2018332191B2 (en) Pharmaceutical composition
KR102238478B1 (ko) 구강 전달용 지방균형잡힌 장쇄 테스토스테론 에스테르
JP2019206540A (ja) プロゲステロン製剤
TW202128150A (zh) ３＇—［（２ｚ）—［１—（３，４—二甲基苯基）—１，５—二氫—３—甲基—５—側氧基—４ｈ—吡唑—４—亞基］肼基］—２＇—羥基—［１，１＇—聯苯基］—３—甲酸及其鹽配製物
RU2779262C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА
JP2003160496A (ja) グリチルリチン経口投与剤
WO2022170398A1 (en) Formulations for improved bioavailability of fenretinide

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231017

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231020

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240515